Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

229 Clinical Updates found
Esther Babady
Patients with profound immunosuppression after undergoing hematopoietic stem-cell transplantation or receiving chimeric antigen receptor (CAR) T cell therapy may shed viable SARS-CoV-2 for at least two months.
Dr. Long Roche with a patient
Receiving five or more cycles of neoadjuvant chemotherapy was associated with worse progression-free survival (PFS) and overall survival (OS) compared to receiving three or four cycles — despite maximal surgical cytoreduction.
Robert Motzer
Everolimus plus bevacizumab demonstrates robust activity in treatment-naïve patients with advanced papillary variant nonclear cell renal cell carcinoma.
Vivian Strong
Total gastrectomy is indicated for patients with stomach cancer gene mutations regardless of family history.
Endocrinologist Dr Eliza Geer
Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Recognizing the significant unmet needs in this cohort, we recently published a review of the latest treatment options.
Radiation Oncologist Dr. Nancy Lee
Our review summarizes recent developments in treatment planning and delivery, existing clinical evidence, and ongoing prospective trials in major head and neck cancers that may further increase the therapeutic window of proton therapy for patients with head and neck cancer.
Urology surgeon Dr. Paul Russo with a colleague
Results from our recent retrospective study show that surgically managed patients with kidney cancer and comorbid mild to moderate chronic kidney disease (CKD) experience significantly less need for future dialysis.
Cultures being placed on tray
Young women with breast cancer who receive neoadjuvant chemotherapy are more likely to decline referral to reproductive endocrinology and infertility specialists than women who receive adjuvant chemotherapy.
Dr Ian Ganly with a patient.
Select patients with papillary thyroid carcinoma with clinically involved lateral neck nodes may not require prophylactic central compartment neck dissection, enhancing quality of life.
Multiple myeloma cell
A single surviving myeloma cell can seed accelerated relapse, and more than 20 percent of nonsynonymous mutations at relapse may be induced by exposure to chemotherapy such as platinum and high-dose melphalan after autologous stem cell transplant.